# A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes

Study · id `cardio:ct-nct04596631` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04596631](<https://clinicaltrials.gov/study/NCT04596631>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04596631

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 132 participants.

## Technical summary

Registry record NCT04596631. Randomized; quadruple masking; primary purpose treatment. Start 2020-11-02 (actual); primary completion 2025-04-29 (actual). Results posted on 2026-08-21.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 132 participants (enrolled count; ClinicalTrials.gov record NCT04596631, source copy `cardio:ctgov-nct04596631-2026-08-21`, retrieved 2026-10-26)
- Started: 2020-11-02 (actual) (ClinicalTrials.gov record NCT04596631, source copy `cardio:ctgov-nct04596631-2026-08-21`, retrieved 2026-10-26)
- Primary completion: 2025-04-29 (actual) (ClinicalTrials.gov record NCT04596631, source copy `cardio:ctgov-nct04596631-2026-08-21`, retrieved 2026-10-26)
- Completion: 2026-02-03 (actual) (ClinicalTrials.gov record NCT04596631, source copy `cardio:ctgov-nct04596631-2026-08-21`, retrieved 2026-10-26)
- Results first posted: 2026-08-21 (ClinicalTrials.gov record NCT04596631, source copy `cardio:ctgov-nct04596631-2026-08-21`, retrieved 2026-10-26)
- Countries: United States; Australia; Austria; Belgium; Czechia; Greece; India; Israel; Lebanon; Malaysia; Mexico; Morocco; Netherlands; New Zealand; North Macedonia; Portugal; Puerto Rico; Romania; Russia; Taiwan; Ukraine; United Kingdom (ClinicalTrials.gov record NCT04596631, source copy `cardio:ctgov-nct04596631-2026-08-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04596631-2026-08-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes
- Acronym: PIONEER TEENS
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Oral semaglutide
- Intervention (Drug): Placebo (semaglutide)
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 23035404ff77489e886fbd1186dcbe2892f2b65177fc76ad007bba8790310522
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
